Céline Féger

Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein in<i>Staphylococcus aureus</i>

Brigitte Malbruny, A. Canu, Bülent Bozdoğan et al. · Antimicrobial Agents and Chemotherapy · 2002 · 82 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +10

Targeted adsorption of molecules in the colon with the novel adsorbent‐based Medicinal Product, DAV132: A proof of concept study in healthy subjects

Jean de Gunzburg, Annie Ducher, Danilo Wegner et al. · The Journal of Clinical Pharmacology · 2014 · 72 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program

Michael J. Dowzicky, George H. Talbot, Céline Féger et al. · Diagnostic Microbiology and Infectious Disease · 2000 · 57 citations

Life Sciences, Infectious Diseases, Pharmacology +12

An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones

Maria J. G. T. Vehreschild, Annie Ducher, Thomas Louie et al. · Journal of Antimicrobial Chemotherapy · 2021 · 48 citations · Full text

Life Sciences, Microbiology, Pharmacology +13

Combination of Quinupristin-Dalfopristin (Synercid) and Rifampin Is Highly Synergistic in Experimental <i>Staphylococcus aureus</i> Joint Prosthesis Infection

Azzam Saleh‐Mghir, Nourdine Ameur, Claudette Muller‐Serieys et al. · Antimicrobial Agents and Chemotherapy · 2002 · 47 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +14